Despite the promise of immunotherapy, single‐agent immune checkpoint blockade has shown limited clinical benefits in pancreatic cancer, which remains largely refractory to immunotherapy.[3, 47] It has been suggested that the CXCR4 pathway modulates the immune microenvironment in pancreatic cancer. This evidence concerns the gene CXCR4 and familial pancreatic carcinoma.